Novel First-in-Class Drug Promising in Early ADHD Study
Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.
How this was made
The 30-second read
Why it matters
The Phase 1B results provide the first human efficacy signal for an orexin‑2 agonist in ADHD, potentially opening a new therapeutic class.
Market read
Positive early data could attract speculative capital and influence the broader ADHD treatment market.
What to watch
The trial size is small (50 patients) and lacks long‑term safety data; market may discount the results until larger studies.
Background
Alkermes is a U.S. biopharma focused on central nervous system disorders. Orexin‑2 agonism is a novel mechanism for ADHD, traditionally treated with stimulants.
Ticker impact
Alkermes reported positive Phase 1B data for its orexin‑2 agonist ALKS 7290 in adult ADHD, showing clinically meaningful symptom improvement.
Potential modest upside in the near term; risk remains until Phase 2 results.
Phase 1B data are material for a biotech; the trial showed clear efficacy and safety signals, which typically lifts sentiment.
Market effects
Strengthens the emerging orexin‑targeted therapeutics niche and may spur competitor pipelines.
U.S. biotech sector could see modest inflows as investors seek exposure to novel ADHD treatments.
Adds to global interest in non‑stimulant ADHD options, potentially influencing international biotech valuations.
Counterpoint
Early‑stage data may be over‑hyped; Phase 2 could reveal safety or efficacy gaps, leading to price correction.
Key entities
- CompanyAlkermes
Developer of ALKS 7290, a first‑in‑class orexin‑2 receptor agonist.
- DrugALKS 7290
Investigational orexin‑2 agonist showing symptom improvement in adult ADHD.
